Bicycle Therapeutics
Focus: Bicycle Therapeutics is a Cambridge-based biotech specializing in peptide drug conjugates (PDCs) for oncology, leveraging proprietary bicyclic peptide technology to target advanced solid tumors.
Profile data last refreshed 14h ago · AI intelligence enriched 2w ago
Open Jobs
3-1 this month
Stable — net -1 jobs in 30d
5 added, 6 removed. Backfill posture.
Should You Work at Bicycle Therapeutics?
AI assessmentBicycle offers a specialized peptide platform and oncology exposure with manageable early-stage risk, suitable for scientists seeking innovation over near-term stability.
Why Work Here
- Cutting-edge platform: proprietary bicyclic peptide technology differentiates the company in a growing PDC market (noted in recent market reports).
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BT1718
Advanced Solid TumoursClinical Trials (1)
NCT03486730BT1718 in Patients with Advanced Solid Tumours.
Phase 1/2Help build intelligence for Bicycle Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.